{"id":115735,"date":"2014-03-12T09:47:23","date_gmt":"2014-03-12T13:47:23","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/scheie-eye-institute-at-the-university-of-pennsylvania-awarded-nih-grant-to-study-the-genetics-of-glaucoma-in-african.php"},"modified":"2014-03-12T09:47:23","modified_gmt":"2014-03-12T13:47:23","slug":"scheie-eye-institute-at-the-university-of-pennsylvania-awarded-nih-grant-to-study-the-genetics-of-glaucoma-in-african","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/scheie-eye-institute-at-the-university-of-pennsylvania-awarded-nih-grant-to-study-the-genetics-of-glaucoma-in-african.php","title":{"rendered":"Scheie Eye Institute at the University of Pennsylvania Awarded NIH Grant to Study the Genetics of Glaucoma in African &#8230;"},"content":{"rendered":"<p><p>Contact Information         <\/p>\n<p>      Available for logged-in reporters only    <\/p>\n<p>    Newswise  (PHILADELPHIA)  Researchers at the Scheie Eye Institute, the department of    Ophthalmology of the University of Pennsylvania have    been awarded a five-year, $11.2 million grant from the National    Institutes of Health (NIH) to study the genetic risk factors    that make African Americans disproportionately more likely to    develop primary open-angle glaucoma (POAG). POAG appears almost    ten years earlier and progresses more rapidly in African    Americans than among Caucasian individuals, making it the    leading cause of irreversible blindness in this population.    Approximately two million Americans suffer from this form of    glaucoma.  <\/p>\n<p>    The goal of our study is to identify the genetic and other    risk factors that underlie POAG in order to understand this    increased burden of disease in African Americans, says    Joan OBrien, MD, chair of the    department of Ophthalmology in Penns Perelman    School of Medicine, director of the Scheie Eye    Institute, and primary investigator on the study.  <\/p>\n<p>    POAG is a group of diseases that cause progressive and    irreversible retinal ganglion cell damage, optic nerve    degeneration, and corresponding visual field loss. Once a    sufficient number of nerve cells are damaged, blind spots begin    to form in the patients peripheral field of vision. Even when    medical and surgical management are employed, retinal ganglion    cell loss can be progressive and irreversible.  <\/p>\n<p>    We aim to understand more about the disease, its causes, and    what makes African Americans more prone to developing POAG at a    younger age and experiencing its most severe form, says    OBrien. Surprisingly, researchers today still have a poor    understanding of what causes POAG, which hinders early    identification and focused treatment of the disease.  <\/p>\n<p>    We know that there is a genetic component to the disease, as    family history has a strong influence, says OBrien. The risk    of developing POAG increases tenfold when a parent or sibling    has the disease, with even larger increases when an identical    twin is affected. By dissecting the disease into subtypes    (called endophenotyping) and understanding the different    genetic underpinnings of the disease, we can begin to develop    better, more targeted treatment options.  <\/p>\n<p>    OBrien will work with Scheie glaucoma specialists, Eydie Miller-Ellis, MD; Prithvi Sankar, MD; and Meredith Regina, MD, PhD, to conduct    a comprehensive genetic analysis of POAG in African Americans.    Their genome-wide analysis will help identify the biological    pathways and networks underlying the disease in 12,766    patients: 4,400 with POAG and 8,365 controls. Additional data    will be provided by the Kaiser Permanente Research Program,    which received ARRA Stimulus funding to analyze 100,000    genomes, with analysis performed in collaboration with Stanford    University. To date, 2,500 Philadelphia-based patients and    controls have been enrolled in the study.  <\/p>\n<p>    Our hypothesis is that genetic variants influence the risk of    POAG and the traits related to that risk, such as intraocular    pressure and corneal and retinal nerve fiber layer thickness.    In addition, we believe that demographic and ocular risk    factors, and medical co-morbidities also contribute to the    increased risk of POAG in African Americans, says OBrien.  <\/p>\n<p>    Once these genomes are analyzed in this understudied and    over-affected population, the data can be used to create a risk    model of POAG in African-Americans, and inexpensively    re-analyzed to elucidate the genetics of other diseases that    disproportionately affect this population.    # # #  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Continue reading here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.newswise.com\/articles\/view\/614875\/?sc=rssn\/RK=0\/RS=KkVLe_cMo6uoJeM90d.QKIC12yo-\" title=\"Scheie Eye Institute at the University of Pennsylvania Awarded NIH Grant to Study the Genetics of Glaucoma in African ...\">Scheie Eye Institute at the University of Pennsylvania Awarded NIH Grant to Study the Genetics of Glaucoma in African ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Contact Information Available for logged-in reporters only Newswise (PHILADELPHIA) Researchers at the Scheie Eye Institute, the department of Ophthalmology of the University of Pennsylvania have been awarded a five-year, $11.2 million grant from the National Institutes of Health (NIH) to study the genetic risk factors that make African Americans disproportionately more likely to develop primary open-angle glaucoma (POAG). POAG appears almost ten years earlier and progresses more rapidly in African Americans than among Caucasian individuals, making it the leading cause of irreversible blindness in this population <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/scheie-eye-institute-at-the-university-of-pennsylvania-awarded-nih-grant-to-study-the-genetics-of-glaucoma-in-african.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[5],"tags":[],"class_list":["post-115735","post","type-post","status-publish","format-standard","hentry","category-genetic-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/115735"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=115735"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/115735\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=115735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=115735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=115735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}